Error 404 - Not Found

Suggestions

FINANCE COMMITTEE QUESTIONS FOR THE RECORD File Format: PDF/Adobe Acrobat - Quick View maker of Vioxx was not forthcoming in its communication with the FDA about the .. chair, has held two investigation and oversight hearings into .. What can you tell the me and my Senate Finance Committee colleagues about plans at

Grassley, Baucus Release Committee Report on Avandia - Committee File Format: PDF/Adobe Acrobat - View as HTML Feb 20, 2010 Baucus, Grassley Release Finance Committee Report on Diabetes Drug Avandia, profile drugs such as Vioxx put public safety at risk because As senior members of the United States Senate and Chairman and Ranking Member of We look forward to hearing from you by no later than March 4, 2010.

Vioxx /David Graham - Government Accountability Project But ODS Chief Dr. Paul Seligman continued the investigation to determine the Senate Finance Committee Chair Charles Grassley (R-Iowa) intervened to ensure the Merck Corporation withdrew Vioxx in the days prior to the hearing ,

USATODAY.com - Merck faces first hearing on Vioxx as lawsuits mount Nov 17, 2004 Merck isn't alone in the investigation spotlight. Today's scheduled hearing by the Senate Finance Committee also focuses on the company's

Congress to investigate Merck, FDA, and the Vioxx withdrawal by DJ Graham Senate Finance Committee broadens FDA investigation Grassley hopes to open some of those doors at the Senate Finance Committee hearing , which will mark

Drug Industry Document Archive United States Senate Finance Committee - Charles Grassley Investigation into payments made to Investigation into the marketing of Vioxx to physicians

For Merck Chief, Credibility at the Capitol - New York Times But yesterday, in a hearing before the Senate Finance Committee that could be a he believed that Merck acted responsibly in dealing with the questions around Vioxx . who heads the committee and has been leading the investigation ,

Critics Diagnose Systemic Maladies of FDA | OMB Watch A Senate Finance Committee hearing on Vioxx and a series of studies by a leading . risk with Vioxx , and to pursue further definitive investigations to

Abstracts: Earlier Merck Study Indicated Risks of Vioxx . For Merck Senate . Committee on Finance , Evidence, Gilmartin, Raymond V. has discontinued the arthritis and pain medication Vioxx because of studies linking it to

News Article : FDA Under Fire from Top Finance Senator Merck voluntarily withdrew Vioxx from the worldwide market in September 2004 after a study At a Senate Judiciary hearing this week, where the government's Alberto Gonzales about the Finance Committee's investigation of Ketek.